【摘要】 目的:研究曲美他嗪联合阿托伐他汀对慢性心力衰竭(CHF)患者的疗效及其机制。方法:109例CHF患者被随机分为常规治疗组(56例)和曲美他嗪联合阿托伐他汀干预组(联合干预组,53例),分别检测两组治疗前、治疗2周及6月后的超敏C反应蛋白(hsCRP)、基质金属蛋白酶(MMP)-9及左室射血分数(LVEF)、左室舒张末内径(LVEDd)的变化。结果:与常规治疗组相比,联合干预组治疗后2周及6月hsCRP[6个月后:(4.47±2.37)mg/L比(3.11±2.04)mg/L]、MMP-9[6个月后:(558.69±210.14)ng/L比(442.77±183.25)ng/L]水平显著降低(P均<0.05),LVEF值显著提高[6个月后:(51.4±4.4)%比(57.3±5.1)%,P<0.05],LVEDd无显著差异(P>0.05);但联合干预组LVEDd较治疗前明显降低[(54.5±6.1)mm比(59.7±6.3)mm,P<0.05]。结论:曲美他嗪联合阿托伐他汀治疗可降低慢性心力衰竭患者超敏C反应蛋白及基质金属蛋白酶-9水平,改善心室重构及心功能。更多还原

【Abstract】 Objective:To study therapeutic effects of trimetazidine(TMZ) combined atorvastatin in patients with chronic heart failure(CHF) and its mechanism.Methods: A total of 109 CHF patients were randomly divided into routine treatment group(n=56) and TMZ + atorvastatin intervention group(combined intervention group,n=53).Changes of levels of high sensitive C reactive protein(hsCRP),matrix metalloproteinase(MMP)-9,left ventricular ejection fraction(LVEF) and left ventricular end-diastolic dimension(LVEDd) were measured and compared between two groups before treatment,two weeks and six months after treatment.Results: Compared with routine treatment group,there were significant decrease in levels of hsCRP [after six months:(4.47±2.37) mg/L vs.(3.11±2.04) mg/L] and MMP-9 [after six months:(558.69±210.14) ng/L vs.(442.77±183.25) ng/L,P<0.05 both],and significant increase in LVEF [after six months:(51.4±4.4) % vs.(57.3±5.1) %,P<0.05] in combined intervention group on two weeks and six months after treatment;the LVEDd was not significant different between two groups after treatment(P>0.05),but LVEDd of combined intervention group was significantly lower than that of before treatment [(54.5±6.1) mm vs.(59.7±6.3) mm,P<0.05].Conclusion: Trimetazidine combined atorvastatin therapy can decrease levels of high sensitive C reactive protein,matrix metalloproteinase-9 and improve ventricular remodeling and cardiac function in patients with chronic heart failure.更多还原